Mesenchymal Stromal Cells Immunosuppress Osteoarthritis Synovial Fluid Modulated Monocytes via IL-6 and CCL2
Mozhgan Rasti, Aida Feiz Barazandeh, Shahrzad Nouri, Kevin P. RobbiD, Rachel Low, O.O. Kolade, Kevin FaniD, Rajiv GandhiiD, Sowmya ViswanathaniD
Abstract
BackgroundMesenchymal stromal cell (MSC) interactions with monocytes/macrophages are central to their therapeutic effects in knee osteoarthritis (KOA); however, mechanisms of these interactions are not fully understood. HypothesisWe hypothesize that MSC soluble factors, particularly interleukin-6 (IL-6) and C-C motif chemokine ligand (CCL2) modulate monocytes in KOA environment. MethodsUsing healthy donor CD14+ monocytes exposed to KOA synovial fluid (SF) in the presence or absence of marrow-derived MSC(M) directly or conditioned medium (CM), we evaluated cell surface markers and signaling via signal transducer and activator of transcription (STAT3), nuclear factor kappa-light-chain-enhancer of activated B (NF-{kappa}B) and c-Jun Terminal Kinase (JNK); functional responses were measured by secretion of tumor necrosis factor (TNF) and IL-1, and by phagocytosis of pHrodo Red E-coli. ResultsCD14+ monocytes demonstrated a mixed phenotype in KOA SF with increased CD163, CD206 and unchanged HLA-DR, CD86 marker expression. This was accompanied by activated STAT3, JNK and NF-{kappa}B signaling. TNF and IL-1 secreted levels were unchanged, but phagocytosis was impaired, indicative of a net dysfunctional repair phenotype and functionality. CD14+ monocytes in KOA SF were hyporesponsive to additional lipopolysaccharide re-challenge, based on TNF and IL-1 secretion. Addition of MSC(M) to KOA SF programmed CD14+ monocytes resolved the dysfunctional phenotype and functionality, with significant increases in CD163, CD206; significant reductions in HLA-DR and CD86 expression; this was accompanied by significantly increased activated STAT3, and decreased activated JNK and NF-{kappa}B. TNF and IL-1 secretion were also significantly reduced, and phagocytic capacity restored. Blocking IL-6, or to a lesser extent, CCL2, partially abrogated MSC(M) soluble factor effects. MSC(M) experienced apoptosis in KOA SF; however, apoptotic bodies did not fully recapitulate MSC(M) soluble factor effects. ConclusionIL-6, CCL2, other soluble factors and apoptotic bodies from MSC(M) secretome mitigate the dysfunctional effects of KOA SF on CD14+ monocytes resulting in immunosuppressed phenotype and functionality.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 1
- FWCI
- 4.42
- Field percentile
- top 5%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Responders vs. non-responders to mesenchymal stromal cells in knee osteoarthritis patients: mechanistic correlates of donor cell attributes and putative patient features
Kevin P. Robb, R. Rabani, … Sowmya Viswanathan·bioRxiv·Jul 17, 2025
- Understanding the effects of mesenchymal stromal cell therapy for treating osteoarthritis using an in vitro co-culture model
- Iron nanoparticle-labeled murine mesenchymal stromal cells in an osteoarthritic model persists and demonstrates anti-inflammatory mechanism of action
A. M. Hamilton, W.-Y. Cheung, … S. Viswanathan·bioRxiv·Mar 8, 2019
- Synovial macrophage activation mediates pain experiences in experimental knee osteoarthritis
G. Blackler, Y. Lai-Zhao, … C. T. Appleton·bioRxiv·Apr 25, 2023
- A PTN-Rich MSC Subtype Promotes Cartilage Repair in End-Stage Knee Osteoarthritis
Ziwei Wang, Luxu Yin, … Yan Zhao·bioRxiv·Nov 9, 2026
- Biomaterial encapsulation of human mesenchymal stromal cells modulates paracrine signaling response and enhances efficacy for treatment of established osteoarthritis
J. M. McKinney, K. A. Pucha, … N. J. Willett·bioRxiv·Jul 30, 2020